Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
ProKidney ( (PROK) ) has issued an announcement.
On May 29, 2025, ProKidney Corp. held its Annual General Meeting where shareholders approved several key proposals, including the company’s domestication from the Cayman Islands to Delaware and the adoption of a new charter. These changes are expected to enhance ProKidney’s corporate governance and operational flexibility, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (PROK) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on ProKidney stock, see the PROK Stock Forecast page.
Spark’s Take on PROK Stock
According to Spark, TipRanks’ AI Analyst, PROK is a Underperform.
ProKidney’s stock score is significantly impacted by its poor financial performance, characterized by weak revenue growth, high operational costs, and negative cash flow. The technical analysis suggests a bearish trend with mixed indicators, while the valuation reflects high volatility and risk due to negative earnings. Overall, the financial instability and operational challenges are the primary concerns, leading to a low stock score.
To see Spark’s full report on PROK stock, click here.
More about ProKidney
Average Trading Volume: 843,687
Technical Sentiment Signal: Sell
Current Market Cap: $210.9M
Learn more about PROK stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue